IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'UniversitÃ© de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Date	Price Target	Rating	Analyst
5/16/2025	$2.00	Buy → Neutral	UBS
5/12/2025		Buy → Hold	Truist
5/9/2025		Mkt Outperform → Mkt Perform	Citizens JMP
10/24/2024	$17.00	Buy	UBS
7/29/2024	$19.00 → $10.00	Overweight → Neutral	Piper Sandler
11/20/2023	$12.00	Buy	Goldman
9/18/2023	$40.00 → $18.00	Overweight	Barclays
5/30/2023	$11.00 → $17.00	Equal Weight → Overweight	Wells Fargo
3/27/2023	$11.00	Equal Weight	Wells Fargo
1/27/2023	$11.00 → $14.00	Neutral → Overweight	Piper Sandler

Iovance Biotherapeutics Inc.

Peers

Recent Analyst Ratings for Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Countouriotis Athena

SEC Form 4 filed by Director Maynard Ryan D

SEC Form 4 filed by Director Weiser Michael

SEC Form 4 filed by Director Dukes Iain D.

SEC Form 4 filed by Director Yarno Wendy L

Chief Commercial Officer Kirby Daniel Gordon bought $55,200 worth of shares (30,000 units at $1.84) (SEC Form 4)

Chief Regulatory Officer Puri Raj K. converted options into 5,469 shares and covered exercise/tax liability with 2,467 shares, increasing direct ownership by 1% to 209,854 units (SEC Form 4)

Interim CEO & General Counsel Vogt Frederick G covered exercise/tax liability with 22,127 shares and converted options into 52,085 shares, increasing direct ownership by 8% to 404,604 units (SEC Form 4)

Chief Medical Officer Graf Finckenstein Friedrich converted options into 12,695 shares and covered exercise/tax liability with 6,448 shares, increasing direct ownership by 7% to 99,160 units (SEC Form 4)

Chief Operating Officer Bilinsky Igor converted options into 12,305 shares and covered exercise/tax liability with 6,250 shares, increasing direct ownership by 7% to 93,633 units (SEC Form 4)